Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

40.81 -0.22 (-0.52%)
Streaming Delayed Price Updated: 1:47 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
QIAGEN delivers solid Q4 2024 growth ahead of outlook
From QIAGEN N.V.
Via Business Wire
News headline image
Earnings Scheduled For February 5, 2025 ↗
 
Via Benzinga
News headline image
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
From QIAGEN N.V.
Via Business Wire
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
Earnings Scheduled For February 6, 2024 ↗
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
News headline image
Earnings Preview: Qiagen ↗
 
Via Benzinga
News headline image
Where Qiagen Stands With Analysts ↗
 
Via Benzinga
News headline image
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
From QIAGEN N.V.
Via Business Wire
News headline image
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker' ↗
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
News headline image
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. 
Via MarketBeat
News headline image
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation ↗
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
News headline image
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches ↗
QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements. 
Via Benzinga
News headline image
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report ↗
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
News headline image
QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024 ↗
QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday? ↗
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc.... 
Via Benzinga
News headline image
US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition ↗
U.S. stocks are looking to build on past week’s gains, with the mood remaining cautiously optimistic. The major index futures were modestly higher in early trading. 
Via Benzinga
Topics Economy
News headline image
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion ↗
Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing... 
Via Benzinga
News headline image
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects ↗
QIAGEN N.V. (NYSE: QGEN) disclosed its expansion plan in  
Via Benzinga
News headline image
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock ↗
Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.